Nanna Lüneborg
General Partner @ Forbion Capital Partners
Amsterdam, The Netherlands
Nanna Lüneborg is a Series B investor at Forbion Capital Partners in Amsterdam focused on Biotechnology and Medical. Nanna Lüneborg is based out of Amsterdam, Noord-Holland. Nanna Lüneborg is the General Partner of Forbion Capital Partners and Board of Directors at MapLight Therapeutics. Nanna previously worked at Novo Holdings as a Partner. Nanna Lüneborg attended the University College London (UCL).
- Total investments:
- 14
- Last investment:
- Lead investor:
- 57%
Last updated:
For AI agents: llms.txt
Industries Nanna Lüneborg invests in
Stages Nanna Lüneborg invests in
Countries Nanna Lüneborg invests in
Investment Focus
Industry
- Biotechnology 11 (79%)
- Medical 6 (43%)
- Health Care 5 (36%)
- Biopharma 4 (29%)
- Life Science 4 (29%)
Stage
- Series B 5 (36%)
- Series C 3 (21%)
- Seed 1 (7%)
- Series A 1 (7%)
- Series D 1 (7%)
Country
- Switzerland 4 (29%)
- United States 3 (21%)
- United Kingdom 2 (14%)
- Canada 1 (7%)
- The Netherlands 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Sparrow Pharmaceuticals
|
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company addressing metabolic dysfunction from excess cortisol. Leveraging underappreciated scientific insights into corticosteroid biology, the company is working to deliver improved outcomes for patients who struggle to control diabetes and related metabolic conditions with currentoptions. Its lead product, clofutriben, is an oral, small molecule, designed to target the source of active intracellular cortisol in key tissues.The company was founded in 2013 by David A. Katz and is based in Portland, Oregon, United States. | $95M / Series B / Sep 24, 2025 | |
MapLight Therapeutics
|
MapLight Therapeutics offers a platform designed to discover and develop therapeutics for brain disorders. It combines single-cell transcriptomics and optogenetics to identify novel drug targets and develop effective therapies for brain disorders. | $372.5M / Series D / Jul 28, 2025 | |
Noema Pharma
|
Noema Pharma is a biotech company developing groundbreaking therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system. Noema’s research and development is focused on understanding and meeting patient needs using our novel therapies. | $147.2M / Series B / Dec 11, 2024 | |
Capstan Therapeutics
|
Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need. | $175M / Series B / Mar 20, 2024 | |
|
Noema Pharma
|
Noema Pharma is a biotech company developing groundbreaking therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system. Noema’s research and development is focused on understanding and meeting patient needs using our novel therapies. | $109.3M / Series B / Mar 07, 2023 | |
Inversago Pharma
|
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $69.3M / Series C / Oct 17, 2022 | |
F2G
|
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversifiedinto chemistry-driven discovery. They have also assembled an experienced development capacity. | $70M / Private Equity / Aug 04, 2022 | |
Numab
|
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases such as chronic inflammation and cancer. It features a plug-and-play platform that substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics. | $110.6M / Series C / May 19, 2021 | |
Lava Therapeutics
|
Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of hematological and solid cancers. Its platform creates and develops next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer as well as develop potent, safe, and cost-effective biopharmaceuticals thatarm the immune system to recognize and destroy tumor cells that enable doctors to safely channel the immune system's response towards tumors. | $83M / Series C / Sep 17, 2020 | |
NodThera
|
NodThera is a Cambridge (UK) headquartered biotech engaged in innate immune/ inflammasome research. Their leading project is focused on developing inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases. | $55M / Series B / Jun 03, 2020 | |
| See all 14 investments → | |||
Co-Investors
About Forbion Capital Partners
Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successfulinvestments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.
Forbion Capital Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Joy Faucher
General Partner
|
|||
Marco Boorsma
General Partner
|
|||
|
Nanna Lüneborg
General Partner
|
|||
Onno Stolpe
Venture Partner
|
|||
Sander Slootweg
Managing Partner and co-founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Nanna Lüneborg invest in?
Nanna Lüneborg invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series C stage. Most of the 14 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Nanna Lüneborg last invest?
The most recent investment recorded for Nanna Lüneborg closed in Sep 2025. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
